Kristaps Klavins

Kristaps Klavins

Auto-generated profile, based on publicly available information

Kristaps Klavins

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090, Vienna, Austria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2017 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
JTJon B. Toledo
Jon B. Toledo
MAMatthias Arnold
Matthias Arnold
GKGabi Kastenmüller
Gabi Kastenmüller
RCRui Chang
Rui Chang
RBRebecca Baillie
Rebecca Baillie
RKRima Kaddurah‐Daouk
Rima Kaddurah‐Daouk

1 December 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
JBJohn A. Bowden
John A. Bowden
AHAlan Heckert
Alan Heckert
CUCandice Z. Ulmer
Candice Z. Ulmer
CJChristina M. Jones
Christina M. Jones
JKJeremy P. Koelmel
Jeremy P. Koelmel
SZSenlin Zhou
Senlin Zhou
John A. Bowden, Alan Heckert, Candice Z. Ulmer, Christina M. Jones, Jeremy P. Koelmel, Laila Abdullah, Linda Ahonen, Yazen Alnouti, Aaron M. Armando, John M. Asara, Takeshi Bamba, John R. Barr, Jonas Bergquist, Christoph H. Borchers, Joost Brandsma, Susanne B. Breitkopf, Tomas Cajka, Amaury Cazenave-Gassiot, Antonio Checa, Michelle A. Cinel, Romain A. Colas, Serge Cremers, Edward A. Dennis, James E. Evans, Alexander Fauland, Oliver Fiehn, Michael S. Gardner, Timothy J. Garrett, Katherine H. Gotlinger, Jun Han, Yingying Huang, Aveline Huipeng Neo, Tuulia Hyötyläinen, Yoshihiro Izumi, Hongfeng Jiang, Houli Jiang, Jiang Jiang, Maureen Kachman, Reiko Kiyonami, Kristaps Klavins, Christian Klose, Harald C. Köfeler, Johan Kolmert, Therese Koal, Grielof Koster, Zsuzsanna Kuklenyik, Irwin J. Kurland, Michael Leadley, Karen Lin, Krishna Rao Maddipati, Danielle McDougall, Peter J. Meikle, Natalie A. Mellett, Cian Monnin, M. Arthur Moseley, Renu Nandakumar, Matej Oresic, Rainey Patterson, David Peake, Jason S. Pierce, Martin Post, Anthony D. Postle, Rebecca Pugh, Yunping Qiu, Oswald Quehenberger, Parsram Ramrup, Jon Rees, Barbara Rembiesa, Denis Reynaud, Mary R. Roth, Susanne Sales, Kai Schuhmann, Michal Laniado Schwartzman, Charles N. Serhan, Andrej Shevchenko, Stephen E. Somerville, Lisa St. John-Williams, Michal A. Surma, Hiroaki Takeda, Rhishikesh Thakare, J. Will Thompson, Federico Torta, Alexander Triebl, Martin Trötzmüller, S. J. Kumari Ubhayasekera, Dajana Vuckovic, Jacquelyn M. Weir, Ruth Welti, Markus R. Wenk, Craig E. Wheelock, Libin Yao, Min Yuan, Xueqing Heather Zhao, Senlin Zhou

21 January 2016 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
RCRamon Casanova
Ramon Casanova
SVSudhir Varma
Sudhir Varma
BSBrittany Simpson
Brittany Simpson
MKMin Kim
Min Kim
YAYang An
Yang An
MTMadhav Thambisetty
Madhav Thambisetty

9 March 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
EGEnrico Girardi
Enrico Girardi
ACAdrián César-Razquin
Adrián César-Razquin
SLSabrina Lindinger
Sabrina Lindinger
KPKonstantinos Papakostas
Konstantinos Papakostas
JKJustyna Konecka
Justyna Konecka
GSGiulio Superti-Furga
Giulio Superti-Furga

1 December 2019 in Immunity
Verified
Journal Article
Open access
ALAlexander Lercher
Alexander Lercher
ABAnannya Bhattacharya
Anannya Bhattacharya
APAlexandra M. Popa
Alexandra M. Popa
MCMichael Caldera
Michael Caldera
MSMoritz F. Schlapansky
Moritz F. Schlapansky
ABAndreas Bergthaler
Andreas Bergthaler
Infections induce complex host responses linked to antiviral defense, inflammation, and tissue damage and repair. We hypothesized that the liver, as a central metabolic hub, may orchestrate systemic metabolic changes during infection. We infected mice with chronic lymphocytic choriomeningitis virus (LCMV), performed RNA sequencing and proteomics of liver tissue, and integrated these data with serum metabolomics at different infection phases. Widespread reprogramming of liver metabolism occurred early after infection, correlating with type I interferon (IFN-I) responses. Viral infection induced metabolic alterations of the liver that depended on the interferon alpha/beta receptor (IFNAR1). Hepatocyte-intrinsic IFNAR1 repressed the transcription of metabolic genes, including Otc and Ass1, which encode urea cycle enzymes. This led to decreased arginine and increased ornithine concentrations in the circulation, resulting in suppressed virus-specific CD8+ T cell responses and ameliorated liver pathology. These findings establish IFN-I-induced modulation of hepatic metabolism and the urea cycle as an endogenous mechanism of immunoregulation. VIDEO

19 February 2015 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
TKTherese Koal
Therese Koal
KKKristaps Klavins
Kristaps Klavins
DSDaniele Seppi
Daniele Seppi
GKGeorg Kemmler
Georg Kemmler
CHChristian Humpel
Christian Humpel
Alzheimer's disease (AD) is a severe and chronic neurodegenerative disorder of the brain. The laboratory diagnosis is limited to the analysis of three biomarkers in cerebrospinal fluid (CSF): amyloid-β 42 (Aβ 42 ), total tau, and phospho-tau-181 (P-tau-181). However, there is a need to find more biomarkers in CSF that can improve the sensitivity and specificity. The aim of the present study was to analyze endogenous small metabolites (metabolome) in the CSF, which may provide potentially new insights into biochemical processes involved in AD. One hundred CSF samples were dichotomized by normal (n = 50) and pathological decreased Aβ 42 and increased tau and P-tau-181 levels (n = 50; correlating to an AD-like pathology). These CSF samples were analyzed using the AbsoluteIDQ ® p180 Kit (BIOCRATES Life Sciences), which included 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, and 90 glycerophospholipids. Our data show that two sphingomyelins (SM (d18:1/18:0) and SM (d18:1/18:1)), 5 glycerophospholipids (PC aa C32:0, PC aa C34:1, PC aa C36:1, PC aa C38:4 and PC aa C38:6), and 1 acylcarnitine (C3-DC-M/C5-OH) were significantly altered in the CSF with pathological “AD-like pathology”. Sphingomyelin SM (d18:1/18:0) proved to be a specific (76%) and sensitive (66%) biomarker with a defined cut-off of 546 nM. Correct diagnoses for 21 out of 32 unknown samples could be achieved using this SM (d18:1/18:0) cut-off value. In conclusion, the sphingolipid SM (d18:1/18:0) is significantly increased in CSF of patients displaying pathological levels of Aβ 42 , tau, and P-tau-181.